Objectives: The purpose of this population-based prospective cohort study was to examine the effect of hormone therapy (HT) on incidence of diabetes mellitus (DM). Design and methods: Eight thousand four hundred and eighty-three DM-free post-menopausal women aged 52-62 from the population-based Kuopio osteoporosis risk factor and prevention study were followed for 5 years from 1994-1999. Information about the use of HT and health events was obtained from three repeated questionnaires in 1989, 1994, and 1999. DM morbidity before and during the follow-up was obtained from the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution. Kaplan-Meyer survival curves and Cox's proportional-hazards models were used to estimate the risk of incident DM in relation to the use of HT. Results: During the follow-up, 40.8% DM-free post-menopausal women had never used HT, 27.3% women were HT past users and 31.9% women had used HT presently during the follow-up. During the follow-up, 162 incident DM cases were recorded. Compared with never users of HT, the adjusted hazard ratio of DM was 0.81 (95% confidence interval (CI) 0.57-1.16) for only past users, 0.53 (95% CI 0.24-1.15) in part-time (during the follow-up !2.5 years) users and 0.31 (95% CI 0.16-0.60) in continuous (during the follow-up 2.5-5.0 years) users of HT. Conclusions: HT use decreases the incidence of DM in post-menopausal women.
Introduction
Diabetes mellitus (DM) is one of the most common chronic diseases in the world. Type 2 DM is increasingly being recognized as a critical health problem especially in middle-aged and elderly people (1) . Obesity and physical inactivity are established risk factors for type 2 DM and cardiovascular comorbidities (2) . It is estimated that the number of diabetic people in the world will double from 171 million in 2000 to 366 million in 2030. Globally, the prevalence of DM is similar in men and women, but it is slightly higher in men under the age of 60 and in women at older ages (3) .
Recent studies have suggested that post-menopausal hormone therapy (HT) is associated with lower incidence of DM. The Heart Estrogen Progestin Replacement Study (HERS) (4) and the Women's Health Initiative (WHI) trials (5, 6) were the first randomized controlled studies showing the positive effects of HT on DM. Primarily, HERS (4) and the WHI (5, 6) studied the effects of HT on cardiovascular disease (CVD) and there was no improvement of cardiovascular outcomes but, on the contrary, a significantly lower incidence of DM among HT users. Some (7) but not all (8, 9) observational studies have also noted a decreased incidence of DM among post-menopausal HT users.
The primary aim of this prospective 5-year study from the population-based study cohort was to examine the effects of HT on the incidence of DM in post-menopausal women.
Materials and methods

Study population
This study is a part of the Kuopio osteoporosis risk factor and prevention population-based prospective cohort study. The target population primarily consisted of the 14 220 women resident in Kuopio Province and born in 1932-41 (aged 52-62 years in 1994) to whom a postal inquiry was sent in May 1989. The study population has been described in detail previously (10) . In all, 13 100 women (92.8%) responded. The second follow-up inquiry was sent to women alive in May 1994. A total of 11 798 women responded to both inquiries. Women whose HT use in May 1994 could not be clarified were excluded (nZ131). A woman was regarded as postmenopausal if R12 months had elapsed since her last natural menstruation or if she had undergone bilateral oophorectomy before May 1994. A total of 839 premenopausal women and women whose menopause could not be defined due to hysterectomy (nZ1146) or to incomplete data (nZ328) were also excluded from the study. Women were considered to have previous DM if they self-reported DM, present use of insulin or oral glucose-lowering medications in 1989 or 1994 and women with that information about DM before the start of follow-up according to the Registry of Specially Refunded Drugs of the Finnish Social Insurance Institution (SII; total nZ282). There were 9072 postmenopausal non-diabetic women in May 1994. In total 8483 (of 9072) post-menopausal women also responded to the third follow-up inquiry in May 1999 which formed the final study population of this study.
This study was approved by the local ethics committee in 1986, 1994, and 1997.
Hormone therapy
The lifetime use of HT in years before the baseline of this study was recorded in two postal enquiries in 1989 and 1994. The duration of HT use in months for each year of follow-up from 1994-1999 was recorded by postal enquiry in 1999. Inconsistent or missing HT information was clarified by telephone interview or by additional postal enquiry. HT use was defined as use of preparations having systemic estrogenic properties, and classified in four categories as follows: never, only in the past (before baseline 1994), part-time (!2.5 years of HT use during the follow-up) and continuous (2.5-5.0 years of HT use during the follow-up). The uniformity of HT use was examined and was found to be approximately uniform throughout the follow-up.
Diabetes
New cases of established DM during the follow-up (nZ162) were ascertained with the Registry of Specially Refunded Drugs of the SII. According to the National Sickness Insurance, the SII granted 100% reimbursement for drug costs in defined chronic illnesses necessitating continuous medication, like DM.
According to the National Sickness Insurance, the criteria for reimbursement of medicines in DM (ICD-9 codes 250.0-250.9 and ICD-10 codes E10-E14, E89.1) are as below:
Examinations and diagnosis of type 1 diabetes (DM1) and type 2 diabetes (DM2) have to be made in the specialized health care unit or by a specialist physician. Owing to high prevalence of DM2, right to reimbursement can be based also upon an opinion from any physician.
I. Patient has the right to reimbursement for DM2 medication when the patient has typical symptoms of DM (polyuria, polydipsia, and glucosuria) and fasting glucose in capillary or vein blood is at least 7.0 mmol/l or in plasma blood at least 8.0 mmol/l. If the symptoms of DM are missing, DM diagnosis has to be confirmed by repeated testing. II. Patient has the right to reimbursement for DM2 medication when the patient has used DM medication for at least 6 months and the positive effects of medication have been described. An overweight DM2 patient must undergo at least 6 months of dietary treatment before medical treatment. The medical certificate concerning DM2 must include information about the duration of diet use and its effects on weight. Furthermore, the symptoms, findings, and blood and urine glucose status and possible albuminuria, especially before medical treatment, may be described. When DM diagnosis has been made, a medical doctor will write the statement to the SII, which will then give the patient the right to reimbursement for DM (The Finnish Social Insurance Institution (Kela); http://www.kela.fi/in/ internet/suomi.nsf/NET/040304095807UK?open Document). In the present study, the date of a physician's statement for DM was used as the endpoint of DM follow-up. In all, 162 post-menopausal women had new incident DM during the follow-up.
Other variables
The inquiries included questions about gynecological history (parity, last menstruation, and menopausal symptoms) and surgery, height, weight, smoking, and chronic health disorders diagnosed by physician (with O100 different items). Present medication prescribed by a doctor was also asked in both inquiries: as well as the names of medications (including duration of use) and diseases that they were taking medications for. SII registry was used together with the inquiries in 1989 and 1994 to determinate the women's baseline status concerning the occurrence of hypertension and hypercholesterolaemia. Body mass index (BMI) was calculated as the ratio of weight in kilograms to height in square meters (kg/m 2 ).
Statistical analysis
The statistical analyses were performed with the SPSS (INC 14.0) program. The differences in baseline characteristics between HT users (during the follow-up) and never users were tested by using ANOVA to compare the means of continuous variables and the c 2 -test to
www.eje-online.org compare categorical variable distributions. P values of !0.05 were considered significant. Kaplan-Meier survival curves with the log rank test were used to examine the effect of HT use on the incidence of DM. KaplanMeier survival curves were also used for evaluation of the applicability of life table models (which assume constant incidence of endpoint events) on our data. Cox's proportional-hazard models were used to study the association of HT use with DM incidence after adjustment for covariates. The covariates used age, parity, BMI, hypertension (no, yes), hypercholesterolaemia (no, yes), status of hysterectomy (no, yes), and smoking history (never, ever). Possible interactive effects of HT use and these covariates on the risk of DM were examined using correlation matrices from Cox's models. Follow-up times were calculated as the time from the 1st of June 1994 to 31st of May 1999 or date of reimbursement decision about DM from SII, whichever came first. P values of !0.05 were considered significant.
Results
Past use of HT was reported by 27.3% and current HT use during the follow-up by 31.9% of the 8483 non-diabetic post-menopausal women during the 5 years follow-up. Mean duration of current HT use during the follow-up was 3.75 years. HT use during follow-up was quite evenly distributed for the 5 years of follow-up. The rest (40.8%) of women had neither used HT nor started it during the follow-up. The average follow-up time was 4.96 years (range 0.04-5.00). There were some marked differences in baseline characteristics between HT users and nonusers (Table 1) . Women who used HT during the follow-up HT were slightly younger, had a lower BMI and had fewer children than non-users. HT users during the follow-up reported slightly less hypertension than never users. Women who used HT only in the past more often had hypertension than never users. HT users had undergone more hysterectomies than never users (Table 1) . During the follow-up, 162 new DM events occurred (nZ8483). The incidence of the DM remained constant throughout the follow-up. Overall, 90 DM incidents were found in HT never users, 51 DM incidents in only past HT users, 8 DM incidents in part-time (!2.5 years) HT users, and 13 DM incidents in continuous (2.5-5.0 years) HT users in the whole cohort ( Table 2 and Fig. 1 
Discussion
In the present population-based 5-year prospective cohort study on post-menopausal women, HT use significantly decreased the risk of developing DM. The risk decrease was accentuated (69%) in women who used HT more than half of the follow-up time. Table 2 The relative risk of incident diabetes (DM) as hazard ratios with 95% confidence interval (CI) in relation to use of hormone therapy (HT) in post-menopausal women during the 5-year follow-up. Multivariate covariates: age, BMI (kg/m 2 ), parity, hypertension (n/y), hypercholesterolemia (n/y), hysterectomy (n/y) and smoking (never, ever).
The strengths of this study include its populationbased nature, detailed information about HT use and careful diagnosis of incident IDDM based on the registry of specially refunded drugs of the SII. The registries in Finland have proven to be reliable (11) . A limitation of our study was that baseline characteristics of current HT users had fewer risk factors than HT non-users. However, adjusting for those characteristics did not affect the results. In addition, no interactions between HT use and these factors were found. Our study did not distinguish between unopposed estrogen and combined therapy or between oral and transdermal application.
Several observational studies and RCTs have examined the role of HT use in the prevention of DM but none of those studies has found as strong a preventive effect as this study (4-7). Manson et al. (7) reported a 20% lower incidence of DM in women using HT compared with women who did not use it in the Nurse's Health Study. In a randomized controlled trial, the HERS study (4), the corresponding decrement was 35%. Lastly, the WHI trial reported 11-17% lowered risk of DM in HT users compared with non-users (5, 6) . On the other hand, the Strong Heart Study (8) reported that the risk of type 2 DM increased by 10% per year of present estrogen use, while Gabal et al. (9) did not find a statistically significant change in DM risk related to HT use.
Unlike these studies, in our present study in postmenopausal women, DM risk reduction related to current HT use during the follow-up was remarkable (62% for all current HT users during the follow-up) compared with never users. The great majority of the women, who used HT during follow-up of our study had started HT before baseline. This long-term HT exposure may partly explain the results of our study. Women who have used HT only in the past and may have stopped the use of HT before the follow-up may have lost part of its benefit, whereas women who have started HT use only a short time ago may not have yet reached the full benefit of it. Finnish women with an intact uterus mainly use oestradiol (OE 2 ) combined with norethisterone acetate or levonorgesterel. Finnish women who have undergone hysterectomy use mainly OE 2 only.
During menopause, women gain body fat in the abdominal region, and insulin sensitivity decreases (12, 13) . These changes, along with dyslipidemia and hypertension, are consistent with the metabolic syndrome and predict DM2 (14) and coronary heart disease (15) in post-menopausal women. HT can have favorable effects on body fat distribution and could, therefore, act to reduce DM risk via this mechanism (16) .
Several studies indicate that estrogen therapy may attenuate the accumulation of central fat in postmenopausal women (17) (18) (19) (20) . In the PEPI trial (21), less weight gain or increase in waist and hip circumferences were registered in women who received ECP therapy compared with placebo. Similarly, in the Danish osteoporosis prevention study (22) , HT use seemed to have a weight-reducing effect.
There are several mechanisms other than effects on adiposity tissue and body fat distribution by which HT may be protective against DM. In a prospective study of older women not using HT, endogenous levels of bioavailable OE 2 and testosterone were positively associated with levels of fasting glucose, insulin, and estimated insulin resistance, whereas only bioavailable testosterone predicted incident DM (23) . Positive associations of bioavailable OE 2 and testosterone with insulin resistance have also been observed in a cross-sectional study of untreated post-menopausal women (24) . Low levels of sex hormone binding globulin are related negatively with obesity, insulin resistance, and incidence of DM in postmenopausal women (25) (26) (27) . Hyperandrogenicity in women is closely associated with insulin resistance and risk factors for CVD and type 2 DM.
It has been hypothesized that estrogen may also have a direct effect on secretion of insulin by the pancreas. For example, estrogen receptors are present in pancreatic b-cells (28) , and estrogen increases the release of insulin in b-cell culture models (29) .
In conclusion, the present prospective cohort study indicates that HT use reduces the risk of DM in postmenopausal women. Further information on the role of HT, according to the route of administration and dose in modifying the risk of DM is needed.
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